MeiraGTx appoints Alan M. Sebulsky to board as Class I director
MeiraGTx appointed Alan M. Sebulsky to its Board of Directors as a Class I director, effective September 23, 2026, and named him to the Science and Technology Committee. Mr. Sebulsky previously spent about 14 years as a Partner and Portfolio Manager at Adage Capital Management, where he managed a biopharmaceutical portfolio, and the company said he brings healthcare investment experience as it transitions to a commercial company.
Key points
- Board appointment effective September 23, 2026; term runs to the 2028 annual meeting of shareholders
- Mr. Sebulsky joins the Science and Technology Committee
- Previously Partner and Portfolio Manager at Adage Capital Management from July 2012 to April 2026; Managing Member of Apothecary Capital LLC since April 2026
- Company states there are no related party transactions with Mr. Sebulsky
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 23, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.